- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A pharmacy director alleged a rep left Palexia/Versatis materials accessible to patients/carers and disparaged pharmacy controls. Panel found the meeting was in…
Astellas admitted a Xtandi e-ad used ‘new indication’ and ‘new publication’ beyond 12 months and included withdrawn/uncertified components due to poor withdrawal…
Anonymous hospital pharmacist questioned Boehringer’s free/discount Ofev supply programme pre-NHS reimbursement, alleging a switch/inducement and lack of clarity. PMCPA found the scheme…
Aegerion sent two “HoFH guidance” emails with Lojuxta prescribing info. The Panel found they were promotional, sent without prior consent, and initially…
Anonymous HCP challenged Seretide promotion using TORCH secondary endpoints despite non-significant primary endpoint (p=0.052). PMCPA found some materials misleading where the primary…
Monofer.com pop-up left “High dose iron in just one visit” visible to the public, breaching the ban on POM advertising. “New” was…
A member of the public alleged Otsuka failed to disclose Samsca (tolvaptan) trial results per ABPI requirements. The Panel found the relevant…
Bayer Schering alleged Lilly promoted Cialis for cardiovascular benefits and low doses based on doctor recall market research. Panel found insufficient evidence…
Anonymous HCP alleged Pfizer’s ESC 2015 exhibition stand was extravagant and created a party atmosphere, citing flavoured iced drinks. Panel found hospitality…
Complaint alleged AstraZeneca’s exhibition stand at a restaurant meeting was visible to the public. Panel found insufficient evidence and accepted precautions (private…
AstraZeneca challenged Janssen’s Invokana materials. Most dosing/compare claims were not breaches, but “flexibility” implied 300mg could be a starting dose and one…
A health professional alleged a Feraccru ad’s claim “safety profile comparable to placebo” was misleading given PI restrictions. The Panel found the…
Complaint about a BBC article calling unlicensed ocrelizumab MS trial results “landmark”. PMCPA assessed Roche’s press release (not the BBC copy) and…
Tor Generics ran a Big Issue ad with a Tor-Bac injection pack shot before MHRA licence. No breach of public POM advertising…
A health board complained about a market research recruitment email offering a ‘finder’s fee’ for AF patient interviews. PMCPA found the survey…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.